Dr. Asim Ahmad, MD
What this data tells you about Dr. Ahmad
Dr. Asim Ahmad is a hematology & oncology in Fort Worth, TX, with 14 years in practice. Based on federal Medicare data, Dr. Ahmad performed 78,961 Medicare services across 1,196 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ahmad received a total of $83,618 from 72 pharmaceutical and/or device companies across 497 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ahmad is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells | 32,340 | $0 | $2 |
| Iron infusion (Feraheme) | 25,500 | $0 | $3 |
| Immune globulin infusion (Octagam) | 9,140 | $33 | $100 |
| Epoetin alfa injection (Procrit) for anemia | 4,000 | $6 | $28 |
| Anti-nausea injection (fosaprepitant) | 2,550 | $0 | $5 |
| Dexamethasone injection (steroid) | 1,530 | $0 | $5 |
| Flow cytometry, additional marker | 460 | $18 | $125 |
| Office visit, established patient, complex (40-54 min) | 369 | $134 | $350 |
| Drug injection, under skin or into muscle | 351 | $11 | $60 |
| Office visit, established patient (30-39 min) | 327 | $91 | $275 |
| Injection of additional new drug or substance into vein | 323 | $12 | $70 |
| Anti-nausea injection (Aloxi/palonosetron) | 290 | $1 | $52 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 224 | $49 | $190 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 193 | $16 | $60 |
| Injection, diphenhydramine hcl, up to 50 mg | 193 | $1 | $10 |
| Hospital follow-up visit, high complexity | 181 | $93 | $250 |
| COVID-19 test, self-administered | 172 | $12 | $30 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 143 | $1 | $5 |
| Administration of chemotherapy into vein, 1 hour or less | 127 | $101 | $412 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 95 | $48 | $160 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 85 | $590 | $1,817 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 66 | $23 | $100 |
| Administration of chemotherapy into vein, each additional hour | 47 | $22 | $93 |
| Office visit, established patient (20-29 min) | 46 | $63 | $175 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 35 | $1,134 | $4,056 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $51 | $202 |
| Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | 26 | $37 | $120 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 26 | $106 | $450 |
| New patient office visit, complex (60-74 min) | 25 | $163 | $500 |
| Flow cytometry technique for dna or cell analysis, first marker | 20 | $56 | $200 |
| Initial hospital admission, moderate complexity | 18 | $101 | $350 |
| Advance care planning consultation, first 30 min | 14 | $65 | $250 |
| Initial hospital admission, high complexity | 11 | $135 | $500 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (53%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 8% for hematology & oncology in TX.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Ahmad is a mixed practice specialist, with above-average Medicare volume (top 11% in TX), and high industry engagement (speaking/promotional, top 8%).
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Ahmad experienced with filgrastim injection (nivestym) for white blood cells?
Does Dr. Ahmad receive payments from pharmaceutical companies?
How do Dr. Ahmad's costs compare to other hematology & oncologys in Fort Worth?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology